SAN FRANCISCO -- February 22, 2010 -- Researchers said here during the 17th Conference on Retroviruses and Opportunistic Infections (CROI) that they could not find a link between most cancers and a diagnosis of AIDS.
During a poster presentation Meredith Shiels, PhD, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, said the researchers did not find a connection between...
ScienceDaily (Feb. 23, 2010) — The presence of certain proteins in premalignant oral lesions may predict oral cancer development, Medical College of Georgia researchers said.
SIBLINGs, or Small Integrin-Binding Ligand N-linked Glycoproteins, are a family of five proteins that help mineralize bone but can also spread cancer. SIBLINGs have been found in cancers including breast, lung, colon and prostate.
"Several years ago we discovered that three SIBLINGs -- osteopontin,...
Premier Jean Charest responded to his critics during a recent trip to India by announcing that he has no plans to ban the sale of asbestos produced in his province. Charest has been under fire from numerous groups for some time now, with criticism reaching a fever pitch during his trip to India for a conference on climate change and sustainable development last week.
Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
MM-121, Merrimack’s lead oncology therapeutic candidate, is an antibody designed to block signaling of ErbB3. This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.
Cambridge, Mass. (PRWEB) February 22, 2010 -- Merrimack...
Reversing Resistance to Sunitinib: Findings May Help Patients With Deadly Kidney Cancer
ScienceDaily (Feb. 19, 2010) — Van Andel Research Institute (VARI) researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment.
